Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
OTHER OTC:SPRB
SPRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.06 - $0.69
Previous CloseN/A
Volume285.87K
Average Volume (3M)1.10M
Market Cap
$2.75M
Enterprise ValueN/A
Total Cash (Recent Filing)$60.05M
Total Debt (Recent Filing)$3.23M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 06, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding42,231,285
10 Day Avg. Volume171,063
30 Day Avg. Volume1,101,205
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.75Price Target Upside1150.00% Upside
Rating ConsensusHold
Number of Analyst Covering4
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Enters Purchase Agreement with Board Chair
PremiumCompany Announcements
Spruce Biosciences Reports Q1 2025 Results and Updates
PremiumCompany Announcements
Spruce Biosciences Acquires TA-ERT for Rare Disease Focus
Bulls Say, Bears Say
Bulls Say
Financial OutlookSpruce Biosciences ended 3Q24 with $60.1M in cash and cash equivalents, which is expected to be sufficient to fund operations at least into 2026.
Regulatory ApprovalThe FDA confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for Accelerated Approval.
Strategic PartnershipsSpruce Biosciences acquired tralesinidase alfa, an enzyme replacement therapy, originally developed by BioMarin, which is in late-stage development and has a seemingly de-risked path to approval.
Bears Say
Clinical SetbacksSpruce Biosciences disclosed disappointing data from recent studies with tildacerfont and has been evaluating strategic opportunities.
Financial ChallengesSPRB's cash balance is now less than $30M and the company is facing significant liquidity pressure.
Operational RisksConcerns exist regarding Spruce Biosciences' ability to fund these programs without further shareholder dilution.
Ownership Overview
13.46% Insiders
2.60% Mutual Funds
17.56% Other Institutional Investors
66.37% Public Companies and Individual Investors
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.06 and its highest was $0.69 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $2.75M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Aug 06, 2025 which is in 59 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on May 06, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.257 by -$0.063.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -0.26.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 42,231,285 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.257. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 0.
Company Description
Spruce Biosciences
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for rare endocrine disorders. The company's primary product candidate, tildacerfont, is being developed to treat congenital adrenal hyperplasia (CAH), a genetic disorder affecting the adrenal glands. Spruce Biosciences operates in the biotechnology and pharmaceuticals sector, aiming to address unmet medical needs in patients with endocrine-related diseases.
SPRB Stock 12 Month Forecast
Average Price Target
$0.75
▲(1150.00%Upside)